Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Dicernatm to Present at the Stifel 2019 Healthcare Conference


Dicernatm Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 11:30 a.m. EST in New York City.

A live audio webcast of the presentation will be accessible within the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicernatm Pharmaceuticals, Inc.

Dicernatm Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The Company's proprietary GalXCtm technology is being applied to develop potent, selective, and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Roche*, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.

*Announced Oct. 31, 2019. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.

Dicernatm and GalXCtm are trademarks of Dicerna Pharmaceuticals, Inc.


These press releases may also interest you

at 09:05
Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had completed software changes and documentation required by the Chinese FDA for...

at 09:05
Octapharma USA and BioMatrix Specialty Pharmacy are supporting a new investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Ky., focused on treating patients with the...

at 09:04
New brand CarryOntm has launched sparkling CBD waters as well as a brand mission to normalize the pursuit of mental wellbeing.  With over 56% of Americans reporting negative effects on their mental wellbeing, CarryOntm believes that the pursuit of...

at 09:00
InspectIR Systems, LLC, a purpose-driven company with proprietary measurement methods, devices and tools, has begun clinical trials aimed at detecting the novel coronavirus (COVID-19). InspectIR partnered with University of North Texas Associate...

at 09:00
CAN Community Health announced that Tampa Family Pharmacy founders Haley Miller and Crystal Campbell have resigned effective immediately and sold their remaining interest to CAN Community Health to spend more time with their respective families....

at 09:00
PTC Therapeutics, Inc. today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5 at 10:00 a.m. ET....



News published on 13 november 2019 at 16:10 and distributed by: